Despite the clear role of autoantibody production in SLE, targeted B cell therapies such as rituximab (anti-CD20) and belimumab (anti-BAFF) have shown only modest efficacy (10–12), particularly in cLN. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.